Omalizumab/Salbutamol

Dr. Christou: This is not the correct option for Amy at this time. Let me explain why. Omalizumab (anti-IgE therapy) is a biological agent reserved for Step 5 treatment of severe asthma with confirmed allergic sensitization and inadequate control on high-dose ICS-LABA combination therapy or other add-on treatments. Amy has mild asthma, so prescribing omalizumab would be premature and inappropriate. Additionally, the use of omalizumab requires specific evaluations, including measuring serum IgE levels and confirmation of allergic asthma.

You are correct that a beta-2 agonist would be beneficial for Amy. Salbutamol, is a short-acting drug and it is normally used in acute settings or as needed, rather than for chronic treatment.

I encourage you to revisit the guidelines for initial asthma management and think about which treatments address both symptom relief and inflammation.

  • Presentation

Map: Amy Cruz (1082)
Node: 20341
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway

  • CULTIVO CELULAR
  • Surgical Referral
  • Glycerol trinitrate (organic nitrate)
  • Theophylline
  • El padre le dice a su hijo.
  • Start
  • Assess the safety of the scene
  • Verify patient identity and obtain e-consent before starting.
  • Salbutamol
  • Start
  • Request permission to record without explaining privacy
  • Dobutamine
  • Go to local cafe
  • Criminal Laboratory Internship
  • If you use antacids, it's better to use sodium bicarbonate
  • Glycerol trinitrate
  • Omalizumab/Salbutamol

Reminder

empty_reminder_msg

FINISH

Time is up